UniProtKB/Swiss-Prot P29460: Variant p.Val298Phe

Interleukin-12 subunit beta
Gene: IL12B
Chromosomal location: 5q31.1-q33.1
Variant information

Variant position:  298
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Polymorphism
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants have been found in patients and disease-association is reported in literature. However, this classification is not a definitive assessment of variant pathogenicity.
  • Polymorphism: No disease-association has been reported.
  • Unclassified: Variants have been found in patients but disease-association remains unclear.

Residue change:  From Valine (V) to Phenylalanine (F) at position 298 (V298F, p.Val298Phe).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and hydrophobic (V) to large size and aromatic (F)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  298
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  328
The length of the canonical sequence.

Location on the sequence:   QGKSKREKKDRVFTDKTSAT  V ICRKNASISVRAQDRYYSSS
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         QGKSKR--------EKKDRVFTDKTSATVICRKNASISVRAQDRYYSSS

Rhesus macaque                QGKSKR--------EKKDRIFTDKTSATVICRKNASFSVQA

Mouse                         QRKKEKMKETEEGCNQKGAFLVEKTSTEVQC-KGGNVCVQA

Pig                           QGKNKR--------EKKDKLFTDQISAKVTCHKDANIRVQA

Bovine                        QGKNKR--------EK--KLFMDQTSAKVTCHKDANVRVQA

Goat                          QGKNKR--------EK--KLFTDQTSAKVTCHKDANIRVQA

Sheep                         QGKNKR--------EK--KLFTDQTSAKVTCHKDANIRVQA

Cat                           QGKNNR--------EKKDRLSVDKTSAKVVCHKDAKIRVQA

Dog                           QGKNNR--------EKKDRLCVDKTSAKVVCHKDAKIRVQA

Horse                         QGKNKK--------ERKDRLFMDETSATVTCHKDGQIRVQA

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 23 – 328 Interleukin-12 subunit beta
Domain 237 – 328 Fibronectin type-III
Beta strand 288 – 298


Literature citations

Submission
SeattleSNPs variation discovery resource;
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS ILE-33 AND PHE-298;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.